A significant body of evidence has been mounted from RCTs and real-world data regarding the infection risk of the different classes of bDMARDs.8 Most of the available data show that the overall incidence of serious infections in bDMARD-treated RA patients ranges between 3–7/100 patient-years, without major differences among the different classes of biologics (anti-TNFs, anti-B cell -rituximab, anti-T/APC cell inhibitors – abatacept, anti-IL6 inhibitors).5,7,8,17,18 This risk appears to be higher during the first year after treatment initiation.15,19. The gene discussed is IL6; the disease is infection.